[Clinical evaluation of cefpiramide in pediatrics].
Cefpiramide (CPM) is a newly developed cephalosporin. Clinical studies on this drug were carried out and the results were as follows; Forty-three patients (purulent lymphadenitis 2, cellulitis 2, purulent otitis media 1, purulent tonsillitis 3, acute bronchitis 2, pneumonia 22, bronchiectasis 1, urinary tract infection 10) were treated with CPM, in doses of 20 approximately 82 mg/kg divided 2 approximately 4 times per day for 3 approximately 11 days intravenously. The overall efficacy rate was 83.7%. As to adverse reaction, 4 cases, which includes 3 cases of diarrhea and 1 case of exanthema, were observed. Abnormal laboratory data noted were liver dysfunction in 3 cases (6.8%), and eosinophilia in 2 cases (4.5%).
D000293:Adolescent; D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male
D002511:Cephalosporins; C036666:cefpiramide